Zobrazeno 1 - 10
of 166
pro vyhledávání: '"Bradley S, Miller"'
Autor:
Cheri L. Deal, Joel Steelman, Elpis Vlachopapadopoulou, Renata Stawerska, Lawrence A. Silverman, Moshe Phillip, Ho-Seong Kim, CheolWoo Ko, Oleg Malievskiy, Jose F. Cara, Carl L. Roland, Carrie Turich Taylor, Srinivas Rao Valluri, Michael P. Wajnrajch, Aleksandra Pastrak, Bradley S. Miller
Publikováno v:
Therapeutic Advances in Endocrinology and Metabolism, Vol 15 (2024)
• The efficacy of weekly somatrogon injections was no different from that of daily somatropin injections to treat children who don’t make enough growth hormone to grow adequately. ○ Efficacy refers to how well a drug works in a clinical trial.
Externí odkaz:
https://doaj.org/article/775d02973cf444caab3d2ae30fd5b795
Autor:
Kevin C J Yuen, Gudmundur Johannsson, Ken K Y Ho, Bradley S Miller, Ignacio Bergada, Alan D Rogol
Publikováno v:
Endocrine Connections, Vol 12, Iss 7, Pp 1-19 (2023)
Growth hormone deficiency (GHD) is a clinical syndrome that can manifest either as isolated or associated with additional pituitary hormone deficie ncies. Although diminished height velocity and short stature are useful and important clin ical marker
Externí odkaz:
https://doaj.org/article/d648e617175949ae9a9510acf8088a7a
Autor:
Roy Gomez, Roger Lamoureux, Diane M. Turner-Bowker, Jane Loftus, Mohamad Maghnie, Bradley S. Miller, Michel Polak, Andrew Yaworsky
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
IntroductionThe standard of care for pediatric growth hormone deficiency (pGHD) is once-daily recombinant human growth hormone (rhGH). Somatrogon, a long-acting rhGH, requires less frequent, once-weekly, dosing. We describe physicians’ preference f
Externí odkaz:
https://doaj.org/article/c25dfd24fe344bf4bef41ceea8b433db
Autor:
Ravi Savarirayan, Wagner Baratela, Thomas Butt, Valérie Cormier-Daire, Melita Irving, Bradley S. Miller, Klaus Mohnike, Keiichi Ozono, Ron Rosenfeld, Angelo Selicorni, Dominic Thompson, Klane K. White, Michael Wright, Svein O. Fredwall
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-10 (2022)
Abstract Background Achondroplasia is associated with disproportionate short stature and significant and potentially severe medical complications. Vosoritide is the first medicine to treat the underlying cause of achondroplasia and data from phase 3
Externí odkaz:
https://doaj.org/article/c1823a2791cb4573bb34654eb99f7e97
Autor:
Merlin G. Butler, Bradley S. Miller, Alicia Romano, Judith Ross, M. Jennifer Abuzzahab, Philippe Backeljauw, Vaneeta Bamba, Amrit Bhangoo, Nelly Mauras, Mitchell Geffner
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Noonan, Turner, and Prader-Willi syndromes are classical genetic disorders that are marked by short stature. Each disorder has been recognized for several decades and is backed by extensive published literature describing its features, genetic origin
Externí odkaz:
https://doaj.org/article/be5ba1ffb43a4445bee8749412bcebc7
Autor:
Bradley S. Miller
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
In standard 52-week phase III clinical trials, once weekly lonapegsomatropin, somatrogon and somapacitan have been found to yield non-inferior height velocities and similar safety profiles to daily GH (DGH) in children with pediatric growth hormone d
Externí odkaz:
https://doaj.org/article/e464c334738e4215a52171a24a9719e2
Autor:
Troy C. Lund, Terence M. Doherty, Julie B. Eisengart, Rebecca L. Freese, Kyle D. Rudser, Ellen B. Fung, Bradley S. Miller, Klane K. White, Paul J. Orchard, Chester B. Whitley, Lynda E. Polgreen
Publikováno v:
JIMD Reports, Vol 58, Iss 1, Pp 89-99 (2021)
Abstract Background Orthopedic disease progresses in mucopolysaccharidosis type I (MPS I), even with approved therapies and remains a major factor in persistent suffering and disability. Novel therapies and accurate predictors of response are needed.
Externí odkaz:
https://doaj.org/article/eda272a015ff42afbdfa8b995f7872ed
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
BackgroundPediatric patients with growth hormone deficiency (GHD) are currently treated with daily injections of recombinant human growth hormone (rhGH) to promote linear growth and enable attainment of normal adult height. One of the main reasons fo
Externí odkaz:
https://doaj.org/article/0fde26a789364c2a826e8261604c9c5d
Autor:
Kevin D. Wright, Bradley S. Miller, Sarah El-Meanawy, Shirng-Wern Tsaih, Anjishnu Banerjee, Aron M. Geurts, Yuri Sheinin, Yunguang Sun, Balaraman Kalyanaraman, Hallgeir Rui, Michael J. Flister, Andrey Sorokin
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-12 (2019)
Abstract Background SHC1 proteins (also called SHCA) exist in three functionally distinct isoforms (p46SHC, p52SHC, and p66SHC) that serve as intracellular adaptors for several key signaling pathways in breast cancer. Despite the broad evidence impli
Externí odkaz:
https://doaj.org/article/38936579b97f4f199df72a29402941f9
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
Externí odkaz:
https://doaj.org/article/d4ff94f5659c457ea385c6900b93d6c6